2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1039

The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response
Abstract Number: 2354

The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Abstract Number: 3086

The Same Multidimensional Patient Health Assessment Questionnaire Used to Assess RAPID3 in Rheumatoid Arthritis, Osteoarthritis and Other Rheumatic Diseases Can Provide Quantitative Clues to Recognize and Document Comorbid Fibromyalgia
Abstract Number: 1075

The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
Abstract Number: 3074

The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire
Abstract Number: 874

The Short Term Damage Burden in Vasculitis and Vasculitis Mimics As Measured By the Vasculitis Damage Index
Abstract Number: 14

The SLE Susceptibility Gene Macrophage Migration Inhibitory Factor Serves As an Upstream Regulator of NLRP3 (NOD-like receptor family pyrin domain containing 3) Expression and Subsequent IL-1beta Production in Human Monocytes in Response to Lupus U1-snRNP Immune Complex
Abstract Number: 2081

The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program
Abstract Number: 2168

The Smoking Paradox in the Development of Myocardial Infarction Among Rheumatoid Arthritis Patients
Abstract Number: 3163

The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Abstract Number: 1205

The Spectrum of Early RA Practice Across the Globe: Results from a Multinational Cross Sectional Survey
Abstract Number: 68

The Stroop Word-Naming Test in Fibromyalgia Patients
Abstract Number: 2063

The Survival Impact of Statins in Psoriasis and Psoriatic Arthritis: A General Population-Based Cohort Study
Abstract Number: 958

The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients
Abstract Number: 1673

The Transcription Factor Nuclear Protein Transcriptional Regulator 1 May Contribute to Increased Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].